Navigation Links
Indivumed Appoints Annette Kassen as Vice President Clinical Research
Date:4/9/2008

HAMBURG, Germany, April 9 /PRNewswire/ -- Indivumed GmbH, the leading provider of products and services enabling the individualized diagnosis and therapy of cancer, announces the appointment of Annette Kassen, Ph.D., to the newly created position of Vice President Clinical Research.

Annette Kassen has spent the last 14 years of her career in basic and clinical research in the field of oncology. At Indivumed she will be responsible for the further development and expansion of the company's clinical research activities and services. Dr Kassen joins from medac GmbH, a Hamburg based pharmaceutical company, where she worked as a project leader conducting phase II/III clinical trials in Europe.

After receiving her Ph.D. from Ruhr-Universitat Bochum in 1994, Annette Kassen was a post-doctoral fellow at Northwestern-University Medical School, Chicago, focussing on the androgen regulation of human prostate cancer cells. She continued her career as Head of Research Laboratories at the University Hospital Department of Urology, Ruhr-Universitat Bochum. She joined medac in 1999 and received her "Masters of Public Health" from Hamburg University of Applied Sciences in 2004.

"Annette Kassen brings with her very valuable knowledge concerning the continuously growing regulatory requirements in clinical research," says Prof. Hartmut Juhl, Chief Executive Officer and Founder of Indivumed. "Moreover, she is a skilful complement to our team and I am confident that Indivumed will benefit from her experience in order to implement and further develop highest clinical research quality standards at Indivumed."

Dr. Kassen said: "There is a great need for effective, sophisticated, and individualized therapies in the treatment of oncologic diseases. Indivumed has the potential to face this challenge successfully and I am very happy to contribute to both the development of new therapeutic strategies as well as the company's success."

About Ind
'/>"/>

SOURCE Indivumed
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... , - Results From ... Rheumatoid Arthritis in Seven Major Industrialized Countries , , ... arthritis say their disease, impacts ... Women living with rheumatoid arthritis find shopping for gifts, ... wrapping presents most, difficult to ...
(Date:12/11/2009)... Dec. 11 Dendreon Corporation (Nasdaq: ... its previously announced public offering have exercised in ... shares of common stock at the public offering ... of the option increases the size of the ... common stock. Dendreon expects to receive net ...
(Date:12/11/2009)... have discovered a new explanation for differences in the severity ... a certain gene, the more serious the handicap. The genetic ... that it is the amount of copies of the GDI1 ... the American Journal of Human Genetics , and are ... connected to VIB, a life sciences research institute in Flanders, ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... Innovative B.C. Technology Promises to Revolutionize Food Processing, ... EnWave Corporation (TSX-V: ENW) ("EnWave" or "the Company") ... sale of its continuous nutraREV(TM) food dehydration equipment ... one of B.C.,s largest blueberry producers. With this ...
... CUREXO Technology Corporation, pioneer in medical robotics ... orthopaedic applications, which is focused on marketing its ... be relocating its headquarters from Sacramento to Fremont ... corporate executives; the remainder of the company will ...
... Big Difference in Managing Indoor and Outdoor AllergiesATLANTA and ... nasal allergy season quickly approaches, people living with nasal ... ward-off allergens before they hit home. To help the ... the spring nasal allergy season, UCB and sanofi-aventis have ...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4CUREXO Technology Corporation Announces New Headquarters 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6
(Date:12/14/2009)... INDIANAPOLIS The most comprehensive study to date of ... regrow appendages may provide important clues to how similar ... at the School of Science at Indiana University-Purdue University ... the amputated limbs of axolotls, a type of salamander ... from any level of amputation, with the hope that ...
(Date:12/14/2009)... use as a defining feature of humans. That,s until examples ... birds and an array of other mammals. Now, a report ... a Cell Press publication, adds an octopus to the growing ... manages a behavioral trick that the researchers call stilt walking. ... coconut shell "bowls," makes its eight arms rigid, and raises ...
(Date:12/14/2009)... As good as laparoscopy is in preventing some of ... have drawbacks, including reduced blood flow and organ dysfunction. Laparoscopy ... small incisions. , By adding another ... area during laparoscopy, researchers at Duke University Medical Center have ... surgery. , The gas ethyl nitrite (ENO) helped to ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2Health and Wellness Partners Inc Says to America Feel the Surge 59568 1Health and Wellness Partners Inc Says to America Feel the Surge 59568 2Health and Wellness Partners Inc Says to America Feel the Surge 59568 3NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 1NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 2NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 3NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 4NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 1NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 2
... University have shown that common bacteria can deliver a ... precisely position sensors, drugs or DNA for the early ... approach represents a potential way to overcome hurdles in ... could be used as an alterative technology for gene ...
... are at double the risk of having a stroke compared ... University of Alberta. It was found that the risk of ... of treatment for Type 2 diabetes and more than doubles ... entered 12,272 subjects into a Type 2 diabetes cohort. All ...
... highly repetitive, gene-poor DNA found in regions of ... dark matter in the universe, the true nature ... of the Drosophila Heterochromatin Genome Project (DHGP), headed ... Lawrence Berkeley National Laboratory, are approaching a complete ...
Other Biology News:Bacteria ferry nanoparticles into cells for early diagnosis, treatment 2Bacteria ferry nanoparticles into cells for early diagnosis, treatment 3Exploring the dark matter of the genome 2Exploring the dark matter of the genome 3Exploring the dark matter of the genome 4Exploring the dark matter of the genome 5Exploring the dark matter of the genome 6
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products: